Aadi Bioscience

Please note: The information displayed on this page might be outdated.
Aadi Bioscience: Aadi is a clinical stage biopharmaceutical company developing precision therapies for genomically defined cancers. Aadi’s primary goal is to bring transformational outcomes to cancer patients with mTOR pathway driver alterations where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety or effective targeting to the disease site. Aadi’s initial focus is on treating patients with aberrant TSC1 or TSC2 genes, tumor suppressors that when mutated are the source of many different cancer types. Aadi’s AMPECT pivotal trial of ABI-009 demonstrated meaningful clinical efficacy in Malignant PEComa, a type of cancer with the highest known mutation rate of TSC1 or TSC2 genes. Based on the AMPECT trial, emerging data for ABI-009 in other solid tumors with TSC1 or TSC2 mutations, and following discussions with the FDA, Aadi is proceeding with a tumor-agnostic registrational trial in cancers harboring TSC1 or TSC2 pathogenic, inactivating mutations with a planned initiation in 2021.

Aadi also has ongoing studies across multiple high unmet need, advanced cancers including colorectal cancer, sarcoma, and glioblastoma to identify activity of ABI-009 in additional mTOR pathway driver alterations and combination regimens.
Sector/Industry:
Healthcare
Characteristics:
Based in...
US - Pacific
Listing
Private
Website:
Profiles:
Address:
Pacific Palisades, CA
United States

Company Participants at Spring Private Company Showcase

Andrew Kwon
Aadi Bioscience, Senior Director BD & Corporate Strategy
Andrew brings 11 years of experience in biotech management consulting focused on Business Development and Commercial Strategy in oncology. He was originally trained as cancer biologist and has held positions as a Research Scientist at Memorial Sloan Kettering Cancer Center and Associate at Radius Ventures. Andrew received a B.S. in Biology from Brown University, Ph.D. in Molecular and Medical Pharmacology from University of California Los Angeles, and M.B.A. from Columbia Business School
Neil Desai
Aadi Bioscience, CEO
Neil is the Founder of Aadi Bioscience, Inc. He was former SVP, Global R&D, Abraxis Bioscience; VP, Strategic Platforms, Celgene Corp; Inventor of the nab® technology, Abraxane® and ABI-009. He successfully led the Abraxane team through all development stages. He has over 25 years of experience in novel therapeutic delivery systems with over 100 issued patents, over 40 peer-reviewed publications and book chapters, and over 200 presentations at scientific meetings. He is an active participant in FDA and EU Nanotechnology initiatives and a member of the Steering Committee for the National Cancer Institute (NCI) Alliance for Nanotechnology in Cancer. He holds board and advisory positions in various start-ups. He holds a M.S and Ph.D. in Chemical Engineering from the University of Texas at Austin, USA, and a B.S. in Chemical Engineering from the University Institute of Chemical Technology in Mumbai, India.

Upcoming Company Event Participation